Enforcement record

Business Suspension Order disclosure naming 一般財団法人化学及血清療法研究所

一般財団法人化学及血清療法研究所 (医薬品医療機器法)

This page records one action from a Japanese government disclosure, including the published name, governing law, authority, action details, and official source.

医薬品医療機器法Ministry of Health, Labour and WelfareGovernment disclosure18 January 2016

Action type

Business Suspension Order

Law

医薬品医療機器法

Authority

Ministry of Health, Labour and Welfare

Action date

18 January 2016

Current page: Enforcement record

This screen focuses on one disclosed action: the published name, governing law, authority, facts, source status, and review evidence.

Source verification

Public-source and preservation status

Publishing authority: Ministry of Health, Labour and Welfare
Official source URL: Recorded by RegBase
Entity match: Not confirmed; shown under the published name
Kiroku preservation: Completed archive verified; Captured: Jul 12, 2026, 03:24 PM JST

“Confirmed” means that RegBase matched this record to the cited public disclosure or entity under the stated checks. It does not verify the truth of the disclosure or guarantee the entity’s current status, creditworthiness, or any legal conclusion.

Open the official source links in the section below to review the original disclosure.

Action summary

Company: 一般財団法人化学及血清療法研究所Japanese only
Original: 一般財団法人化学及血清療法研究所
Governing law: 医薬品医療機器法
医薬品医療機器法
Action type: Business Suspension Order
業務停止命令
Action date: 18 January 2016
Issuing authority: Ministry of Health, Labour and Welfare
厚生労働省
Industry context: 医薬品医療機器

Violation

Machine-translated summary — verify against original

The Ministry of Health, Labour and Welfare has issued an administrative suspension order to the General Incorporated Foundation, Chemical and Serum Therapy Institute, based on Article 75, Paragraph 1 of the Pharmaceuticals and Medical Devices Act, for a period of 110 days from January 18, 2016 (Monday) to May 6, 2016 (Friday).

Show original Japanese text

厚生労働省では、本日付けで、一般財団法人化学及血清療法研究所に対し医薬品医療機器法第75条第１項の規定に基づき、別紙のとおり平成28年１月18日(月)から同年５月６日(金)までの110日間の業務停止命令(行政処分)を行いましたので、お知らせします。

Compliance context

High

A formal order requiring suspension of business activities for the covered scope or period.

Japanese regulatory disclosure under 医薬品医療機器法.

Escalate for legal or third-party risk review before onboarding or continuing a material relationship.

This context is an operational aid for review workflows, not a credit opinion or legal conclusion.

Open original sources and verification detailsOfficial URL, direct PDF, and Kiroku archive

Original Ministry of Health, Labour and Welfare source (Japanese)Open preserved source and evidence pack

Extracted at: 2026-04-24T23:34:23.912+00:00
Evidence checked: 2026-04-24T23:34:23.912+00:00
Archive captured: 2026-07-12T06:24:34.07897+00:00

Show audit JSON

{
  "record": {
    "id": "26d42f29-3d7e-4ca6-b555-c4d1cfb1f896",
    "url": "https://regbase.jp/en/enforcement/other-hua-xue-ji-xie-qing-liao-fa-yan-jiu-suo-20160118",
    "company_name_original": "一般財団法人化学及血清療法研究所",
    "company_name_registry": null,
    "corporate_number": null,
    "law": {
      "ja": "医薬品医療機器法",
      "en": "医薬品医療機器法"
    },
    "action_type": {
      "ja": "業務停止命令",
      "en": "Business Suspension Order"
    },
    "authority": {
      "ja": "厚生労働省",
      "en": "Ministry of Health, Labour and Welfare"
    }
  },
  "entity_match": {
    "status": "unresolved",
    "confidence": 85,
    "method": "nta_strict_name_nationally_unique",
    "method_label": "nta_strict_name_nationally_unique",
    "notes": "NTA full-download lookup found a nationally unique exact registered-name candidate (一般財団法人化学及血清療法研究所). No Corporate Number was present in the disclosure, so this remains a likely match."
  },
  "review": {
    "status": "unreviewed",
    "label": "Machine extracted"
  },
  "compliance_context": {
    "severity": "High",
    "actionMeaning": "A formal order requiring suspension of business activities for the covered scope or period.",
    "practicalNote": "Escalate for legal or third-party risk review before onboarding or continuing a material relationship.",
    "lawContext": "Japanese regulatory disclosure under 医薬品医療機器法."
  },
  "evidence": {
    "recordUrl": "https://regbase.jp/en/enforcement/other-hua-xue-ji-xie-qing-liao-fa-yan-jiu-suo-20160118",
    "officialSourceUrl": "https://www.mhlw.go.jp/stf/houdou/0000108663.html",
    "officialDocumentUrl": null,
    "archiveUrl": "https://kiroku.today/a/aa596a4b22hemg04",
    "archivedSourceUrl": "https://www.mhlw.go.jp/stf/houdou/0000108663.html",
    "archiveCapturedAt": "2026-07-12T06:24:34.07897+00:00",
    "extractedAt": "2026-04-24T23:34:23.912+00:00",
    "translatedAt": "2026-05-01T06:50:08.227+00:00",
    "evidenceCheckedAt": "2026-04-24T23:34:23.912+00:00",
    "generatedAt": "2026-09-18T19:21:19.848Z"
  },
  "limitations": [
    "RegBase aggregates public Japanese government disclosures and does not provide a credit opinion.",
    "English summaries are provided for reference. The original Japanese source is authoritative.",
    "Possible or unresolved entity matches should be manually verified before use in a decision."
  ]
}

The original Japanese disclosure is the authoritative record. Use possible or unresolved matches only as leads for manual review.

Language

日本語版を見る (Japanese)

About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.